Skip to main content
SpringerLink
Log in

Fractures and Healing on Antiresorptive Therapy

  • Chapter
Book cover The Duration and Safety of Osteoporosis Treatment

  • 949 Accesses

Abstract

The greatest predictor for future fragility fractures is prior fracture. Due to the high morbidity and mortality of these subsequent fractures, as well as the substantial hospital and social cost, it is imperative to start patients on osteoporosis medications as soon as possible after fracture. But which medications are safe to start and when can they be started? We review the current literature surrounding osteoporosis medications and their effect on fracture healing in the osteoporotic patient.

None of the medications reviewed in this chapter were shown to delay fracture healing of fractures, with the exception of a potential delay in the healing of stress fractures with antiresorptive agents. The anabolic medications, including PTH and anti-sclerostin antibody, show some evidence supporting their role in potential acceleration of fracture healing. With a few noted exceptions explained in this chapter, we feel that it is safe to start anti-osteoporosis medications for patients as soon as possible after fracture. There are currently some new and exciting medications in trial for the treatment of osteoporosis that need further study on their effects on fracture healing. The current literature on these new therapies is also reviewed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    *Important References

References

*Important References

  1. *Goldhahn J, Féron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W, Mitlak B, Tsouderos Y, Boonen S. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012;90(5):343–53. *This is important as a consensus article from the European Society on Osteoporosis regarding a broad selection of osteoporosis medications.

    Article  PubMed  CAS  Google Scholar 

  2. *Larsson S, Fazzalari NL. Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg. 2014;134(2):291–7. *This is important as a surgeon’s perspective on fracture healing on osteoporosis medications.

    Article  PubMed  Google Scholar 

  3. Jørgensen NR, Schwarz PS. Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep. 2011;9(3):149–55.

    Article  PubMed  Google Scholar 

  4. *Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809. *This is a seminal paper from a large well-run trial that garnered international attention.

    Article  PubMed  CAS  Google Scholar 

  5. Matos MA, Tannuri U, Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol. 2010;11(1):7–12.

    Article  PubMed  PubMed Central  Google Scholar 

  6. McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008;43(4):653–62.

    Article  PubMed  CAS  Google Scholar 

  7. *Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C, HORIZON Recurrent Fracture Trial. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int. 2011;22(8):2329–36. *Another seminal paper from a well-run trial that garnered attention and is influential in the timing of when IV bisphosphonates can safely be started.

    Article  PubMed  Google Scholar 

  8. Harding AK, W-Dahl A, Geijer M, Toksvig-Larsen S, Tägil M. A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthop. 2011;82(4):465–70.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19(11):1779–86.

    Article  PubMed  CAS  Google Scholar 

  10. Pizones J, Plotkin H, Parra-Garcia JI, Alvarez P, Gutierrez P, Bueno A, Fernandez-Arroyo A. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop. 2005;25(3):332–5.

    Article  PubMed  Google Scholar 

  11. Amanat N, Brown R, Bilston LE, Little DG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005;23(5):1029–34.

    Article  PubMed  CAS  Google Scholar 

  12. Madsen JE, Berg-Larsen T, Kirkeby OJ, Falch JA, Nordsletten L. No adverse effects of clodronate on fracture healing in rats. Acta Orthop Scand. 1998;69(5):532–6.

    Article  PubMed  CAS  Google Scholar 

  13. Adolphson P, Abbaszadegan H, Bodén H, Salemyr M, Henriques T. Clodronate increases mineralization of callus after Colles’ fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand. 2000;71(2):195–200.

    Article  PubMed  CAS  Google Scholar 

  14. Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, Ominsky MS, Kostenuik PJ, Morgan EF, Einhorn TA. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009;24(2):196–208.

    Article  PubMed  CAS  Google Scholar 

  15. Saito M, Shiraishi A, Ito M, Sakai S, Hayakawa N, Mihara M, Marumo K. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone. 2010;46(4):1170–9.

    Article  PubMed  CAS  Google Scholar 

  16. Fu LJ, Tang TT, Hao YQ, Dai KR. Long-term effects of alendronate on fracture healing and bone remodeling of femoral shaft in ovariectomized rats. Acta Pharmacol Sin. 2013;34(3):387–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Uchiyama S, Itsubo T, Nakamura K, Fujinaga Y, Sato N, Imaeda T, Kadoya M, Kato H. Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J. 2013;95-B(11):1544–50.

    Article  PubMed  CAS  Google Scholar 

  18. Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg [Am]. 2009;34(4):595–602.

    Article  Google Scholar 

  19. *Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. J Bone Joint Surg Am. 2012;94(19):1729–36. *This is a good paper from an orthopaedic surgeon’s perspective showing that early treatment with bisphosphonates does not slow healing.

    PubMed  Google Scholar 

  20. Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg (Br). 2012;94(7):956–60.

    Article  Google Scholar 

  21. Savaridas T, Wallace RJ, Salter DM, Simpson AH. Do bisphosphonates inhibit direct fracture healing?: a laboratory investigation using an animal model. Bone Joint J. 2013;95-B(9):1263–8.

    Article  PubMed  CAS  Google Scholar 

  22. Beil FT, Barvencik F, Gebauer M, Seitz S, Rueger JM, Ignatius A, Pogoda P, Schinke T, Amling M. Effects of estrogen on fracture healing in mice. J Trauma. 2010;69(5):1259–65.

    Article  PubMed  CAS  Google Scholar 

  23. Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Women’s Health. 2013;13:15.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Stuermer EK, Sehmisch S, Rack T, Wenda E, Seidlova-Wuttke D, Tezval M, Wuttke W, Frosch KH, Stuermer KM. Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat. Langenbecks Arch Surg. 2010;395(2):163–72.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Spiro AS, Khadem S, Jeschke A, Marshall RP, Pogoda P, Ignatius A, Amling M, Beil FT. The SERM raloxifene improves diaphyseal fracture healing in mice. J Bone Miner Metab. 2013;31(6):629–36.

    Article  PubMed  CAS  Google Scholar 

  26. *Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. *This is a well-run trial that was published in NEJM showing the benefit of RANK-L inhibitors on the treatment of osteoporosis.

    Article  PubMed  CAS  Google Scholar 

  27. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012;27(7):1480–6.

    Article  PubMed  CAS  Google Scholar 

  28. *Adami S, Libanati C, Boonen S, Cummings SR, Ho PR, Wang A, Siris E, Lane J, FREEDOM Fracture-Healing Writing Group, Adachi JD, Bhandari M, de Gregorio L, Gilchrist N, Lyritis G, Möller G, Palacios S, Pavelka K, Heinrich R, Roux C, Uebelhart D. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94(23):2113–9. *This is another paper out of the large FREEDOM trial published in the orthopaedic literature that shows that the RANK-L inhibitors do not interfere with fracture healing.

    Article  PubMed  Google Scholar 

  29. Zhang D, Potty A, Vyas P, Lane J. The role of recombinant PTH in human fracture healing: a systematic review. J Orthop Trauma. 2014;28(1):57–62.

    Article  PubMed  Google Scholar 

  30. Andreassen TT, Fledelius C, Ejersted C, Oxlund H. Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand. 2001;72(3):304–7.

    Article  PubMed  CAS  Google Scholar 

  31. *Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87(4):731–41. *This is a good study that shows, at least experimentally, that anabolic agents can accelerate the rate of fracture healing.

    Article  PubMed  Google Scholar 

  32. Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, Seki A, Sun YX, Yamamoto T. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007;40(6):1475–82. Epub 2007 Feb 2.

    Article  PubMed  CAS  Google Scholar 

  33. *Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14. *Similar to the Alkhiary study, this too shows that Teriparatide can accelerate fracture healing, this time in a human study.

    Article  PubMed  CAS  Google Scholar 

  34. *Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop. 2010;81(2):234–6. *This article is important as it shows how acceleration can occur, in this instance through the improvement in early callus formation.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–7.

    Article  PubMed  Google Scholar 

  36. Agholme F, Isaksson H, Li X, Ke HZ, Aspenberg P. Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop. 2011;82(5):628–32.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Suen PK, He YX, Chow DH, Huang L, Li C, Ke HZ, Ominsky MS, Qin L. Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. J Orthop Res. 2014;32(8):997–1005.

    Article  PubMed  CAS  Google Scholar 

  38. Soung DY, Gentile MA, Doung LT, Drissi H. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice. Bone. 2013;55(1):248–55. Epub 2014 Feb 26.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedics, UCLA, 1250 16th St., Suite 23100, Santa Monica, CA, 90404, USA

    Eli Kupperman MD & Susan V. Bukata MD

Authors
  1. Eli Kupperman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan V. Bukata MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan V. Bukata MD .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center; University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA

    Stuart Silverman

  2. Institute of Clinical Research; Department of Medicine, Holbæk, Denmark, University of Southern Denmark, Odense Patient Data Explorative Network; Holbæk Hospital, Odense, Denmark

    Bo Abrahamsen

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kupperman, E., Bukata, S.V. (2016). Fractures and Healing on Antiresorptive Therapy. In: Silverman, S., Abrahamsen, B. (eds) The Duration and Safety of Osteoporosis Treatment. Springer, Cham. https://doi.org/10.1007/978-3-319-23639-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23639-1_18

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23638-4

  • Online ISBN: 978-3-319-23639-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation